GI Dynamics Announces Additional Members to Its Scientific Advisory Board
June 19 2017 - 6:44PM
Business Wire
GI Dynamics® Inc. (ASX:GID), a medical device company that has
commercialized EndoBarrier® in Europe, the Middle East and South
America for patients with type 2 diabetes and obesity announced
additional members of the GI Dynamics Scientific Advisory Board
(SAB), bringing together distinguished physicians and scientists
specializing in endocrinology, gastroenterology and
bariatric/metabolic surgery. Francesco Rubino, MD, and Philip
Schauer, MD have joined the GI Dynamics SAB.
The GI Dynamics SAB was designed to advance the body of evidence
and state of patient care through EndoBarrier utilization. The SAB
will serve as a key resource to GI Dynamics during its
Investigational Device Exemption clinical trial in the United
States and will support ongoing clinical studies and
commercialization in the United Kingdom, Germany, the Middle East
and select European countries.
“We are delighted to have Dr. Rubino and Dr. Schauer join the GI
Dynamics SAB and we look forward to collaborating with them,” said
Scott Schorer, GI Dynamics president and chief executive officer.
“Dr. Rubino is a pioneer in the field and has helped lead the
evolution of bariatric surgery towards metabolic surgery, created
the thought process regarding GI tract involvement in the
pathophysiology of type 2 diabetes, and independently developed the
animal model proof of the EndoBarrier mechanism of action. Dr.
Schauer brings a focus on severe obesity and the pathophysiology of
type 2 diabetes, is a leading researcher in the disease state, and
has performed over 7,000 procedures for type 2 diabetes and
obesity.”
Dr. Rubino is internationally recognized as one of the world
leaders in the research, education, and practice of metabolic and
weight-loss surgery. He received his MD and completed his residency
in general surgery at the Catholic University in Rome, Italy. Dr.
Rubino completed fellowships in laparoscopic surgery at the
European Institute of Telesurgery in Strasbourg, France, at Mount
Sinai Medical Center, New York, and at the Cleveland Clinic.
A member of many professional organizations, Dr. Rubino is the
recipient of numerous awards, has given hundreds of presentations
throughout the world, and is the author of over 100 articles in
peer-reviewed journals as well as numerous book chapters. His
experimental studies provided the first evidence of a direct effect
of gastrointestinal surgery on glucose metabolism independent of
weight loss, uncovering a biological link between the gut and
diabetes. Dr. Rubino was the main organizer and co-director with
Dr. Lee Kaplan and GI Dynamics SAB members Dr. Cummings and Dr.
Schauer of the Diabetes Surgery Summit (DSS), an influential
consensus conference. The recently released DSS guidelines have
been adopted by the American Diabetes Association, and have been
endorsed by over 50 scientific societies around the world. Dr.
Rubino also served as Congress Director and organizer of the first
three editions of the World Congress on Interventional Therapies
for Type 2 Diabetes, an international forum for discussion of both
conventional surgical interventions and novel endoluminal
approaches.
“The potential impact of EndoBarrier for the treatment of both
type 2 diabetes and obesity in less obese patients is truly
exciting,” says Dr. Rubino. “I look forward to working with the GI
Dynamics SAB to further study EndoBarrier and its many benefits for
patients.”
Dr. Schauer is the past president of the American Society for
Metabolic and Bariatric Surgery and immediate past chair of Obesity
Week. He has also served as a co-director of the DSS with Drs.
Cummings, Kaplan and Rubino. His clinical areas of expertise
include laparoscopic and gastrointestinal surgery. Dr. Schauer
received his medical degree from the Baylor College of Medicine,
completed his residency in surgery at The University of Texas at
San Antonio, and completed his fellowship in laparoscopic surgery
at Duke University Medical Center.
Dr. Schauer is board certified in surgery by the American Board
of Surgery. He has been the principal investigator or
co-investigator on numerous research grants and has published
numerous papers, abstracts, and book chapters related to
gastrointestinal and laparoscopic surgery. His memberships in
professional and scientific societies include the American College
of Surgeons, Association of Academic Surgery, Society of University
Surgeons, Society of Laparoendoscopic Surgeons, American Society of
Bariatric Surgery, Society of American Gastrointestinal and
Endoscopic Surgeons (SAGES), and Society for Surgery of the
Alimentary Tract.
“EndoBarrier is bridging the gap in care for patients struggling
to control their HbA1c levels with ever-increasing doses of insulin
but do not meet the criteria for gastric bypass surgery”, says Dr.
Schauer. “I am excited to help advance the tools that will provide
a powerful treatment option for this patient population.”
About GI Dynamics
GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the
first endoscopically-delivered device approved for the treatment of
type 2 diabetes and obesity. EndoBarrier is not approved for sale
in the United States and is limited by federal law to
investigational use only in the United States. Founded in 2003, GI
Dynamics is headquartered in Boston, Massachusetts. For more
information, please visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
the potential for EndoBarrier as an important treatment option for
patients with type 2 diabetes and obesity. These forward-looking
statements are based on GI Dynamics management’s current estimates
and expectations of future events as of the date of this
announcement. Furthermore, the estimates are subject to several
risks and uncertainties that could cause actual results to differ
materially and adversely from those indicated in or implied by such
forward-looking statements. These risks and uncertainties include
but are not limited to, risks associated with obtaining funding
from third parties; the consequences of stopping the ENDO trial and
the possibility that future clinical trials will not be successful
or confirm earlier results; the timing and costs of clinical
trials; the timing of regulatory submissions; the timing, receipt
and maintenance of regulatory approvals; the timing and amount of
other expenses; the timing and extent of third-party reimbursement;
risks associated with commercial product sales, including product
performance, competition, market acceptance of products,
intellectual-property risk; risks related to excess inventory; and
risks related to assumptions regarding the size of the available
market, the benefits of our products, product pricing, timing of
product launches, future financial results and other factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. Given these uncertainties, one should not
place undue reliance on these forward-looking statements. We do not
assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information
or future events or otherwise, unless we are required to do so by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619006336/en/
GI Dynamics, Inc.Investor RelationsUnited States:Janell
Shields, +1-781-357-3280investor@gidynamics.comorMedia
RelationsUnited States:Nicole Franklin,
+1-617-657-1312nfranklin@jpa.com
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024